AAD 2004

Drug Profile

AAD 2004

Alternative Names: AAD-2004

Latest Information Update: 20 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurotech Pharmaceuticals
  • Developer AmKor Pharma; GNT Pharma
  • Class Anti-inflammatories; Antidementias; Antiparkinsonians; Salicylates; Small molecules; Sulfonamides
  • Mechanism of Action Amyloid beta-protein inhibitors; Antioxidants; Free radical scavengers; Prostaglandin-E synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Amyotrophic lateral sclerosis; Arthritis; Depressive disorders; Diabetes mellitus; Pancreatitis; Parkinson's disease
  • Preclinical Pain

Most Recent Events

  • 19 Oct 2016 AAD 2004 series have patent protection for the treatment of pain and inflammation (GNT Pharma website, October 2016)
  • 19 Oct 2016 GNT Pharma has patent protection for AAD 2004 in the EU, Canada, Japan, China and the US (GNT Pharma website; October 2016)
  • 19 Oct 2016 GNT Pharma plans a phase I/II trial in Alzheimer's disease (GNT Pharma website; October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top